Log In
Copyright © 2008 American Chemical Society
July 21, 2008 Cover
Volume 86, Issue 29
COVER: Molecular fragments that bind to a disease-relatedprotein become motifs for drug discovery efforts.
Volume 86, Issue 29
DRUG DISCOVERY
More and more companies are using fragment-based lead design as a drug discovery strategy
COVER: Molecular fragments that bind to a disease-relatedprotein become motifs for drug discovery efforts.
Credit: DayvaGebhart/Rigaku
» Full Article
July 21, 2008 Issue
Volume 86, Issue 29
July 21, 2008 Issue, Vol. 86 | Iss. 29
More and more companies are using fragment-based lead design as a drug discovery strategy
(pp. 15-23)
Features
Business
Preregistration for chemical regulation program settles in after a few teething problems (pp. 27-29)
Government & Policy
Obama is at odds with chemical industry on key energy and trade issues (pp. 35-41)
News of the Week
Lightweight Atoms Imaged
New method renders conventional instruments capable of 'seeing' hydrogen atoms
(p.9)Ashland To Buy Hercules For $3.3 Billion
Deal will create firm focused on additives, paper, and resins
(p.11)Support For Masters Of Science
Professional science master's degree programs are vital and must be funded, NRC report states
(p.11)Departments
Business
Preregistration for chemical regulation program settles in after a few teething problems
(pp. 27-29)
DSM's pharma products unit leverages its biotech strength to survive in a tough environment
(pp. 30-31)
N-Methylpyrrolidone enabled environmentally friendlier products, but now it has toxicity problems
(p.32)
More and more companies are using fragment-based lead design as a drug discovery strategy
(pp. 15-23)Concentrates
(pp. 24-25)
(pp. 24-25)- Yara Buys Fertilizer Plant
- Linde Secures Silane Supplies ...
- ... And Offers Alternative To NF3
- SABIC Streamlines European Aromatics
- Cognis Sheds Fiber Treatments
- Paper Mill May Make Diesel Fuel
- Cristal To Buy Titanium Firm
- Dow Names CEO For Kuwait Venture
- New York Gets High-Tech Investments
- Lonza Snares Novartis Contract
- Pacific Biosciences Wins Financing
- ViroPharma To Buy Lev For $443 Million
- Amgen Settles With J&J For $200 Million
- GSK To Collaborate On Insomnia Drug
- Business Roundup
Government & Policy
Obama is at odds with chemical industry on key energy and trade issues
(pp. 35-41)
New program for high-risk research is poised to award first grants, but future funding is unclear
(p.42)Education
Bayer’s worldwide educational programs show students and the public the wonder of science
(pp. 55-57)
Science & Technology
Amyloid fibrils are hallmarks of disease but also may provide a basis for advanced nanomaterials
(pp. 48-50)
An artist discovers her visual icon in a life-or-death medical moment
(pp. 52-53)